Director/PDMR Shareholding
Updated : 14:48
Hikma Pharmaceuticals PLC
Notification and public disclosure of transactions by persons discharging managerial responsibilities
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Mohammed 'Ali' Al-Husry |
2 | Reason for the notification | |
a) | Position/status | Non-Executive Director |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| Mr. Al-Husry has a beneficial interest in DKYB Limited, which holds shares in Hikma. DKYB Limited previously had 1,109,748 Hikma shares pledged to Citibank Switzerland. On 19 November 2019 the pledge arrangement was changed so that 989,748 shares were pledged to Citibank Jersey and 120,000 shares were pledged to Citibank Switzerland. Both Citibank Switzerland and Citibank Jersey are ultimately wholly owned by Citigroup Inc.
|
c) | Price(s) and volume(s) | Price(s): £0.00p Volume(s): 0 |
d) | Aggregated information | Aggregated volume: 0 Price: £0.00p |
e) | Date of the transaction | 19 November 2019 |
f) | Place of the transaction | London |
Peter Speirs, Company Secretary, Responsible for releasing this announcement
21 November 2019
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.